PRKAA1 and ovarian carcinoma: This implies that a combination of chemotherapy with novel agents eliciting LKB1-AMPK pathway inhibition would be efficacious as an upfront approach to treat ovarian cancer patients with late-stage disease to better eradicate residual dormant micro-metastases and reduce chemo-resistant disease recurrence.